VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer
VivoSim Labs (NASDAQ:VIVS) has appointed Tony Lialin as Chief Commercial Officer to scale its AI-enabled NAMkind™ liver and intestine toxicology services. The company operates in the $641M global liver and gastrointestinal in-vitro models and toxicology services market, with services representing 53.1% of revenue.
The U.S. accounts for $325M (50.8%) of the global liver toxicology market, with the in vitro liver model segment growing at a 5.9% CAGR from 2020-2024. VivoSim Labs combines 3D human tissue models with AI analytics to deliver early-stage toxicology insights for pharmaceutical development, capitalizing on increasing adoption of non-animal testing methodologies supported by FDA Modernization Act 2.0.
VivoSim Labs (NASDAQ:VIVS) ha nominato Tony Lialin Chief Commercial Officer per potenziare i servizi di tossicologia epatica e intestinale NAMkind™ supportati dall'IA. L'azienda opera nel mercato globale dei modelli in vitro e dei servizi di tossicologia per fegato e tratto gastrointestinale da $641M, dove i servizi rappresentano il 53.1% dei ricavi.
Negli Stati Uniti si concentra $325M (50.8%) del mercato globale della tossicologia epatica, con il segmento dei modelli epatici in vitro in crescita a un CAGR del 5.9% fra il 2020 e il 2024. VivoSim Labs combina modelli tissutali umani 3D con analisi basate su IA per fornire insight tossicologici nelle fasi precoci dello sviluppo farmaceutico, sfruttando la crescente adozione di metodi non animali favorita dalla FDA Modernization Act 2.0.
VivoSim Labs (NASDAQ:VIVS) ha nombrado a Tony Lialin Chief Commercial Officer para escalar sus servicios de toxicología hepática e intestinal NAMkind™ habilitados con IA. La compañía opera en el mercado mundial de modelos in vitro y servicios de toxicología para hígado y sistema gastrointestinal de $641M, donde los servicios representan el 53.1% de los ingresos.
Estados Unidos representa $325M (50.8%) del mercado global de toxicología hepática, y el segmento de modelos hepáticos in vitro creció a un CAGR del 5.9% entre 2020 y 2024. VivoSim Labs combina modelos tisulares humanos 3D con analítica de IA para ofrecer conocimientos toxicológicos en etapas tempranas del desarrollo farmacéutico, aprovechando la mayor adopción de métodos sin animales respaldada por la FDA Modernization Act 2.0.
VivoSim Labs (NASDAQ:VIVS)는 AI 기반 NAMkind™ 간 및 장 독성 서비스의 확장을 위해 Tony Lialin을 최고상업책임자(Chief Commercial Officer)로 임명했습니다. 회사는 전 세계 간 및 위장관 인비트로 모델·독성 서비스 시장 규모 $641M에서 사업을 운영하며, 서비스가 매출의 53.1%를 차지합니다.
미국은 전 세계 간 독성 시장의 $325M(50.8%)를 차지하며, 인비트로 간 모델 부문은 2020~2024년 기간 동안 연평균 성장률(CAGR) 5.9%로 성장했습니다. VivoSim Labs는 3D 인간 조직 모델과 AI 분석을 결합해 제약 개발 초기 단계에서 독성 평가 인사이트를 제공하며, FDA Modernization Act 2.0이 뒷받침하는 비동물 검사 방법의 확대를 활용합니다.
VivoSim Labs (NASDAQ:VIVS) a nommé Tony Lialin Chief Commercial Officer pour développer ses services de toxicologie hépatique et intestinale NAMkind™ assistés par IA. La société opère sur le marché mondial des modèles in vitro et services de toxicologie pour le foie et le système gastro-intestinal de $641M, les services représentant 53.1% du chiffre d'affaires.
Les États-Unis représentent $325M (50.8%) du marché mondial de la toxicologie hépatique, le segment des modèles hépatiques in vitro affichant un CAGR de 5.9% pour la période 2020-2024. VivoSim Labs associe des modèles tissulaires humains 3D à des analyses IA pour fournir des insights toxicolologiques en phase précoce du développement pharmaceutique, tirant parti de l'adoption croissante de méthodes sans animaux soutenue par la FDA Modernization Act 2.0.
VivoSim Labs (NASDAQ:VIVS) hat Tony Lialin zum Chief Commercial Officer ernannt, um die KI-gestützten NAMkind™-Toxikologieservices für Leber und Darm auszubauen. Das Unternehmen ist tätig im globalen Markt für in-vitro-Modelle und Toxikologieservices für Leber und Gastrointestinaltrakt in Höhe von $641M, wobei Services 53.1% des Umsatzes ausmachen.
Die USA entfallen auf $325M (50.8%) des globalen Marktes für Lebert toxikologie, wobei das Segment der in-vitro-Lebermodelle zwischen 2020 und 2024 mit einem CAGR von 5.9% gewachsen ist. VivoSim Labs verbindet 3D-Mensch-Gewebemodelle mit KI-Analytik, um frühzeitige toxikologische Erkenntnisse für die Arzneimittelentwicklung zu liefern und profitiert von der zunehmenden Akzeptanz nicht-tierischer Testverfahren, gestützt durch den FDA Modernization Act 2.0.
- Global market size of $641M for liver and gastrointestinal in-vitro models and toxicology services
- Strong U.S. market presence with 50.8% ($325M) market share
- Positive industry growth with 5.9% CAGR in liver model market
- Strategic hire of experienced commercial leader with track record in scaling life science platforms
- Regulatory tailwinds from FDA Modernization Act 2.0 supporting adoption
- Highly competitive market requiring significant commercial scaling efforts
- Heavy reliance on successful execution of AI integration with biological models
Veteran commercial leader to scale AI-enabled NAMkind™ liver and intestine toxicology services in a rapidly growing market
SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim Labs”), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (“3D”) human tissue models of liver and intestine, announced today that it has appointed Tony Lialin as its Chief Commercial Officer.
Mr. Lialin brings more than two decades of experience turning breakthrough life science platforms into scalable, predictable revenue. He has built commercial teams from the ground up, forged strategic pharma partnerships, and helped scale multiple businesses that were later acquired by leading industry players. At VivoSim Labs, he will lead go-to-market strategy, partnerships, and the expansion of the Company’s San Diego-based services that combine organ-specific 3D models with AI-driven analytics to deliver decision-ready insights earlier in development.
Market Opportunity: According to an internal analysis conducted by VivoSim Labs in July 2025, the global combined liver and gastrointestinal in-vitro models and toxicology services market generated
Category Tailwinds: Biopharma sponsors are accelerating the use of non-animal new approach methodologies (NAMs). Regulatory momentum, including the FDA Modernization Act 2.0 (2022), supports validated alternatives and is catalyzing broader adoption of human-relevant in vitro models for ADME and toxicology.
How AI Helps: VivoSim Labs applies AI to quantify multi-parametric toxicity signatures across liver and intestinal organoid assays. By improving signal-to-noise in dose-response analyses, the platform helps project teams prioritize candidates and plan studies with greater confidence.
“VivoSim Labs sits at the intersection of biology and AI. Our NAMkind™ models are designed to answer make-or-break questions earlier,” said Tony Lialin, Chief Commercial Officer, VivoSim Labs. “We will scale a high-touch, consultative service from our San Diego lab so pharma and biopharma teams get decision-ready toxicology insights that aim to streamline pre-IND decision-making and reduce late-stage surprises.”
“Tony has a rare track record of turning disruptive science into durable commercial engines,” said Keith Murphy, Executive Chairman, VivoSim Labs. “As sponsors move rapidly to 3D, human-relevant models, they want a partner—not just a plate or a protocol—to guide critical decisions. Tony knows how to build the solutions that our customers need.”
About VivoSim Labs
VivoSim Labs, Inc. ("VivoSim" and the “Company”), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (“3D”) human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies ("NAM") models. The Company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration (“FDA") announcement on April 10, 2025 to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA. Visit www.vivosim.ai.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding expansion of the Company’s San Diego-based services; the potential for the Company’s organ-specific 3D models and AI-driven analytics to deliver decision-ready insights earlier in development; the market opportunity and market size of gastrointestinal in-vitro models and toxicology services; and the ability of the Company’s services to improve signal-to-noise in dose-response calls or help project teams prioritize candidates and studies with greater confidence. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. These risks and uncertainties and other factors are identified and described in more detail in the Company’s filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on June 5, 2025, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on August 12, 2025. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events.
Contact
Investor Relations
info@vivosim.ai
VivoSim Labs, Inc.
FAQ
Who is Tony Lialin and what is his role at VivoSim Labs (VIVS)?
What is the market size for VivoSim Labs' (VIVS) services in 2024?
How does VivoSim Labs (VIVS) use AI in their toxicology services?
What is the growth rate of the in vitro liver model market?
How does the FDA Modernization Act 2.0 impact VivoSim Labs (VIVS)?
